Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Thymosin-α-1; Tα 1; Zadaxin

Latest Information Update: 27 Sep 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas at Austin
  • Developer SciClone Pharmaceuticals; sigma-tau SpA
  • Class Adjuvants; Antineoplastics; Antivirals; Oligopeptides; Thymus hormones
  • Mechanism of Action Immunostimulants; T-lymphocyte subset modulators; Th1 cell stimulants; Th2-cell-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Hepatitis B; Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Malignant melanoma

Highest Development Phases

  • Marketed Cancer; Hepatitis B; Hepatitis C
  • Phase III Sepsis
  • No development reported Liver cancer; Malignant melanoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Sep 2016 SciClone Pharmaceuticals plans a phase I/II trial for Non-small cell lung cancer (Metastatic disease) in Italy (NCT02906163)
  • 11 Mar 2016 SciClone Pharmaceuticals has patent protection for thymalfasin in China (SciClone Pharmaceuticals, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top